Munro Group

As we close the book on 2022 it is time to look at how far the AIBN has come during the year, and how we are setting ourselves up for an even bigger 2023.

A new UQ company aims to change the game for chronic pain patients by delivering new, hyper targeted medication.

Professor Trent Munro has joined the Advisory Board of Macrobiome Therapeutics.

AIBN Professor Trent Munro is leading a team to develop, test and manufacture specific therapeutics in Australia, including for use against COVID-19.

A pilot facility at AIBN could be producing mRNA vaccines and cancer therapies for research and development within months after receiving backing from the Australian Government.